By Sneha S K and Sriparna Roy (Reuters) -Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes,​ including a potential sale, and warned it could launch a proxy fight if no progress ‌is made in the next four months. In a second letter to Novavax's board in less than a month, shared exclusively with ‌Reuters on Wednesday, Shah Capital said it has become "increasingly disenchanted" with the company's weak COVID-19 vaccine sales.

As the late spring heat escalates, having the right home apparatuses can fundamentally improve your solace and make your residing space

Before the appearance of Europeans in the New World, California flaunted a shocking semantic variety, with more than 200 unmistakable Local